(Reuters) - Portola Pharmaceuticals Inc said late-stage data showed its oral anticoagulant was not superior to an injectable standard therapy in preventing blood clots in acutely ill patients.
http://ift.tt/1WKS95b
from Reuters: Health News
via animenewspro
Aucun commentaire:
Enregistrer un commentaire